EUVIMEDEUVIMED entdecken
Open Access

SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors

Riku Suzui iD, Mana Taki, Sachiko Kitamura, Masumi Sunada, Koji Yamanoi, Ryusuke Murakami, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Masaki Mandai

International Cancer Conference Journal · 17.09.2024 · 13 (4) · 515-519

DOI: 10.1007/s13691-024-00721-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Cancer Conference Journal, online erschienen am 17.09.2024. Verfasst von Riku Suzui und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507 Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SMARCA4-deficient tumors have been reported in various organs and are associated with a poor prognosis. SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) was first described in 2018. Conversely, loss of SMARCA4 (BRG1) expression, as observed by immunostaining, has been observed in several cases of undifferentiated endometrial carcinoma. SDUS has considerable morphologic overlap with undifferentiated endometrial carcinoma, while there are differences in their clinicopathological features. Here, we present two cases of SMARCA4-deficient uterine tumors in patients in their 20 s: SDUS (Case 1) and undifferentiated endometrial carcinoma without SMARCA4 nuclear expression (Case 2). Using comprehensive genome profiling, we found that both cases had SMARCA4 mutations, with tumor mutation burdens of 0 and 68 Muts/Mb, respectively. Case 1 had multiple lung metastases 9 months after surgery. We treated the patients with combination of an immune checkpoint inhibitor (pembrolizumab) and a multikinase inhibitor (lenvatinib), and the response to the treatment was stable. This study presents the first report on the response to immune checkpoint inhibitor and multikinase inhibitor in SDUS. Supplementary Information: The online version contains supplementary material available at 10.1007/s13691-024-00721-2.

Schlagwörter

Stichwörter der Autor:innen

ICIsSDUSSMARCA4Undifferentiated endometrial carcinoma

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507 Japan.
  • Department of Diagnostic Pathology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

ORCID-Profile: Riku Suzui

Zitieren

APA

Suzui, R., Taki, M., Kitamura, S., Sunada, M., Yamanoi, K., Murakami, R., Yamaguchi, K., Hamanishi, J., Minamiguchi, S., & Mandai, M. (2024). SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors. International Cancer Conference Journal, 13(4), 515-519. https://doi.org/10.1007/s13691-024-00721-2

Vancouver

Suzui R, Taki M, Kitamura S, Sunada M, Yamanoi K, Murakami R, et al. SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors. International Cancer Conference Journal. 2024;13(4):515-519. doi:10.1007/s13691-024-00721-2

BibTeX
@article{Suzui2024,
  author = {Suzui, Riku and Taki, Mana and Kitamura, Sachiko and Sunada, Masumi and Yamanoi, Koji and Murakami, Ryusuke and Yamaguchi, Ken and Hamanishi, Junzo and Minamiguchi, Sachiko and Mandai, Masaki},
  title = {SMARCA4-deficient uterine tumors in young women: response to immune checkpoint inhibitors},
  journal = {International Cancer Conference Journal},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {515--519},
  doi = {10.1007/s13691-024-00721-2}
}
Kostenlos starten →